Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1988 Jun;32(6):834–837. doi: 10.1128/aac.32.6.834

Bone penetration of enoxacin in patients with and without osteomyelitis.

I W Fong 1, B R Rittenhouse 1, M Simbul 1, A C Vandenbroucke 1
PMCID: PMC172291  PMID: 3166359

Abstract

Enoxacin concentrations in bone were measured in 24 patients without infection and in 7 with osteomyelitis after one or two doses of 400 mg of enoxacin administered orally or intravenously. Enoxacin concentrations were measured in serum and bone (cortical and cancellous) by high-pressure liquid chromatography. The mean concentration in serum was 2.4 +/- 1.0 micrograms/ml (range, 1.3 to 5.2 micrograms/ml) and was highest after two intravenous doses (3.1 +/- 0.9 micrograms/ml). The mean concentration in cortical bone was 1.0 +/- 0.9 micrograms/g (range, 0.4 to 4.8 micrograms/g) and was highest in patients with osteomyelitis (1.3 +/- 1.6 micrograms/g), but this was not statistically significant. The concentration of enoxacin in cancellous bone was significantly higher than that in cortical bone, with a penetration of 82 versus 40%. Oral enoxacin in practical doses can provide significant levels in bone, and further studies are warranted to determine its therapeutic efficacy in osteomyelitis.

Full text

PDF
834

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bauernfeind A., Ullmann U. In-vitro activity of enoxacin, ofloxacin, norfloxacin and nalidixic acid. J Antimicrob Chemother. 1984 Sep;14 (Suppl 100):33–38. doi: 10.1093/jac/14.suppl_c.33. [DOI] [PubMed] [Google Scholar]
  2. Chin N. X., Neu H. C. In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim. Antimicrob Agents Chemother. 1983 Nov;24(5):754–763. doi: 10.1128/aac.24.5.754. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Fong I. W., Ledbetter W. H., Vandenbroucke A. C., Simbul M., Rahm V. Ciprofloxacin concentrations in bone and muscle after oral dosing. Antimicrob Agents Chemother. 1986 Mar;29(3):405–408. doi: 10.1128/aac.29.3.405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Fong I. W., Vandenbroucke A., Simbul M. Penetration of enoxacin into bronchial secretions. Antimicrob Agents Chemother. 1987 May;31(5):748–751. doi: 10.1128/aac.31.5.748. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Nakamura S., Minami A., Katae H., Inoue S., Yamagishi J., Takase Y., Shimizu M. In vitro antibacterial properties of AT-2266, a new pyridonecarboxylic acid. Antimicrob Agents Chemother. 1983 May;23(5):641–648. doi: 10.1128/aac.23.5.641. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Norden C. W. Experimental osteomyelitis. II. Therapeutic trials and measurement of antibiotic levels in bone. J Infect Dis. 1971 Dec;124(6):565–571. doi: 10.1093/infdis/124.6.565. [DOI] [PubMed] [Google Scholar]
  7. Siporin C., Towse G. Enoxacin: worldwide in-vitro activity against 22451 clinical isolates. J Antimicrob Chemother. 1984 Sep;14 (Suppl 100):47–55. doi: 10.1093/jac/14.suppl_c.47. [DOI] [PubMed] [Google Scholar]
  8. Tsuei S. E., Darragh A. S., Brick I. Pharmacokinetics and tolerance of enoxacin in healthy volunteers administered at a dosage of 400 mg twice daily for 14 days. J Antimicrob Chemother. 1984 Sep;14 (Suppl 100):71–74. doi: 10.1093/jac/14.suppl_c.71. [DOI] [PubMed] [Google Scholar]
  9. Wolf R., Eberl R., Dunky A., Mertz N., Chang T., Goulet J. R., Latts J. The clinical pharmacokinetics and tolerance of enoxacin in healthy volunteers. J Antimicrob Chemother. 1984 Sep;14 (Suppl 100):63–69. doi: 10.1093/jac/14.suppl_c.63. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES